Zantac Lawsuit

Zantac voluntary recall

Sold both over-the-counter and as a prescription, Zantac is one of H2 (histamine-2) blockers used to decrease the amount of acid in the stomach. Over-the-counter versions are used to treat common conditions such as heartburn and indigestion. Prescription options of the product are also available to treat and prevent more severe conditions, such as ulcers and gastroesophageal reflux disease.

Zantac manufacturer Sanofi recalled certain batches of the drug in October 2019 amid concerns that they may contain NDMA, a possible carcinogen. The recall included:  

Zantac 150®
Zantac 150® Cool Mint
Zantac 75®

Multiple manufacturers of generic versions of the popular antacid also announced recalls, including Appco Pharma and Northwind Pharmaceuticals in January 2020. Mylan also recalled batches of a similar prescribed antacid, nizatidine, due to the presence of the potentially toxic substance. Read more.

Zantac cancer lawsuit investigation

Motley Rice is currently investigating reports of stomach, bladder, kidney, pancreatic and colon cancer related to Zantac heartburn medications. NDMA is an organic compound that may also be found in water and certain foods, including meats, dairy products, and vegetables, according to the FDA. Laboratory tests indicate that NDMA can cause cancer in humans. The FDA began investigating it and similar toxins in blood pressure and heart failure medications in 2018 and says that it has found “unacceptable levels” of NDMA in some ranitidine products.

Consult a medical professional before stopping or changing any medication.

Motley Rice LLC, a South Carolina Limited Liability Company, is engaged in the New Jersey practice of law through Motley Rice New Jersey LLC. Esther Berezofsky attorney responsible for New Jersey practice.